Skip to content

Clinical observation on the application of intraoperative cell salvage in cesarean section with dangerous placenta previa

Clinical observation on the application of intraoperative cell salvage in cesarean section with dangerous placenta previa

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089675
Enrollment
Unknown
Registered
2024-09-12
Start date
2024-09-20
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dangerous placenta previa

Interventions

intraoperative cell salvage group:Autologous blood transfusion without leukocyte filter
Non-transfused control group:No blood transfusions or blood products were given
White blood cell filter set:Autologous blood was transfused and filtered through a leukocyte filter
Allogeneic blood transfusion group:Transfusion of allogeneic blood as needed

Sponsors

Tianjin Central Hospital of Gynecology and Obstetrics
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 39 Years

Inclusion criteria

Inclusion criteria: 1. Age 20-39 years old, ASA physical status classification II. 2. Estimated intraoperative blood loss =500ml. 3. Normal mental state, no communication barriers. 4. Aware of this study, voluntarily enrolled, with good compliance, and actively cooperating with the research

Exclusion criteria

Exclusion criteria: 1. RH negative blood type. 2. Patients with cardiovascular system, autoimmune system, endocrine and other systemic organ functional diseases, or acute fatty liver /HELLP syndrome. 3. Anticoagulation, antiplatelet and other related drugs were used two weeks before surgery, or preoperative platelet < 50 × 109 /L or preoperative PT and APTT were prolonged by more than 1.5 times. 4. Women who received allogeneic blood transfusion 3 months before surgery or participated in other clinical trials during pregnancy.

Design outcomes

Primary

MeasureTime frame
Metabonomics;Fetal and amniotic fluid components;

Secondary

MeasureTime frame
Inflammatory factor;Blood routine examination;Blood clotting function test;

Countries

China

Contacts

Public ContactZhiqiang Yu

Tianjin Central Hospital of Gynecology and Obstetrics

120yuzhi@163.com+86 138 2076 1323

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026